Research led by the CDC and conducted at seven academic pediatric medical centers in the United States finds nirsevimab (sold as Beyfortus) highly effective in reducing respiratory syncytial virus (RSV) related hospitalization in children under 5 years old.
Medical Xpress – latest medical and health news stories
Discover more from Nurse Unity Chats
Subscribe to get the latest posts sent to your email.
